LOGIN
WCO-IOF: Teriparatide injected once weekly reduces fracture risk regardless of subgroup
April 2014
WCO-IOF: Teriparatide injected once weekly reduces fracture risk regardless of subgroup
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Once-weekly teriparatide reduces vertebral fracture risk: Subgroup analysis from the Teriparatide Once Weekly Efficacy Research (TOWER) trial
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
In a previous randomized controlled trial, 542 patients (65-95 years) with osteoporosis were randomized to receive an injection of 56.5 mg teriparatide or a placebo injection, once weekly, to determine the effect of this treatment approach on vertebral fracture risk. The purpose of the current analysis was to determine whether the effects remain in a variety of subgroups. Results indicated that si...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.